1-Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID19). https://covid.cdc.gov/covid-data-tracker/#vaccinations. Accessed on June 3, 2021.
2-Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID19). https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html. Accessed on May 18, 2021.
3-Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
4-Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384:403-416. DOI: 10.1056/NEJMoa2035389
5-Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR. 2021:70(13);495–500.
6-Angel Y, Spitzer A, Henig O, et al. Association Between Vaccination with BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA. Published online May 06, 2021. doi:10.1001/jama.2021.7152
7-Benenson S, Oster Y, Cohen MJ, Nir-Paz R. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers. N Engl J Med. Published online March 23, 2021. doi:10.1056/NEJMc2101951
8-Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. N Engl J Med. 2021; 384:1774-1775. DOI: 10.1056/NEJMc2101927
9-Daniel W, Nivet M, Warner J, Podolsky DK. Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center. N Engl J Med. Published on line March 23, 2021. DOI: 10.1056/NEJMc2102153
10-Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-877. doi:10.1016/S0140-6736(21)00448-7
11-Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in healthcare workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725–35. DOI:https://doi.org/10.1016/S0140-6736(21)00790-X.
12-Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel, Clin Infect Dis. 2021; ciab361, https://doi.org/10.1093/cid/ciab361
13- Birhane M, Bressler S, Chang G, et al. COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021. MMWR. 2021:70(21);792-973. DOI: http://dx.doi.org/10.15585/mmwr.mm7021e3.
14-Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID19). https://chfs.ky.gov/Pages/cvdaily.aspx. Accessed on May 18, 2021.
15-Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID19). https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed May 18, 2021.
16-Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html. Accessed May 28, 2021.
17-Chu H, Halloran ME. Bayesian estimation of vaccine efficacy. Clin Trials. 2004;1(3):306-14. doi.org/10.1191/1740774504cn025oa
18-Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020;25(32):1-5. doi:10.2807/1560-7917.ES.2020.25.32.2001483
19-Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 Infection in a community treatment center in the Republic of Korea. JAMA Intern Med. 2020;180(11):1447-1452. doi:10.1001/jamainternmed.2020.3862
20-Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med. 2020;173(5):362-367. doi:10.7326/M20-3012